Successful treatment of immune-related Grover´s disease with isotretinoin

Teresa Kränke; Birger Kränke

doi:10.5826/dpc.1602a6613

Successful treatment of immune-related Grover´s disease with isotretinoin

Authors

Teresa Kränke Department of Dermatology, Medical University of Graz, Austria https://orcid.org/0000-0001-8406-6063
Birger Kränke Department of Dermatology and Venereology, Augenbruggerplatz 8 Medical University of Graz, Austria

Keywords:

Grover´s disease, immune-checkpoint inhibitor, dermoscopy, isotretinoin

Author Biography

Teresa Kränke, Department of Dermatology, Medical University of Graz, Austria

Teresa Maria Kränke, MD Deputy Head of the Skin Cancer Unit Department of Dermatology and Venereology, Graz University Hospital Auenbruggerplatz 8 A- 8036 Graz E-mail: teresa.kraenke@medunigraz.at

References

Moodie D, Dunn C, Fernandez C, Nathoo R. Retinoids for the treatment of refractory Grover´s disease: A case series and review of the literature. Cureus 2024;16(2):e53510. DOI:10.7759/cureus.53510. PMID: 38440005.

Wongvibulsin S, Pahalyants V, Kalinich M et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United Stated population-level analysis. J Am Acad Dermatol. 2022;86(3):563-572. DOI: 10.1016/j.jaad.2021.03.094. PMID: 33819538.

Khazaeli M, Grover R, Pei S. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma. J Cutan Pathol. 2023;50(6):520-523. DOI: 10.1111/cup.14383. PMID: 36601731.

Lacarrubba F, Boscaglia S, Nasca MR, Caltabiano R, Micali G. Grover´s disease: Dermoscopy, reflectance confocal microscopy and histopathological correlation. Dermatol Pract Concept. 2017;7(3):51-54. DOI: 10.5826/dpc.0703a11. PMID: 29085721.